AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05093803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALTH APP GROUP
Description: Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
Study NCT00828152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT.
Description: 12 weeks. Therapist contact through e-mail.
Study NCT00828152 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: On line discussion group
Description: Placebo. On line discussion group.
Study NCT00004263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine (UCN-01)
Description: 20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
Study NCT00004263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
Study NCT04464070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: niacin
Description: induce biosynthesis of PGD2
Study NCT04464070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: inhibition of cyclooxygenase
Study NCT00695552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
Study NCT00695552 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low impact exercise
Description: Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
Study NCT03113695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
Study NCT03113695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
Study NCT03113695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDMP
Description: methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
Study NCT00606983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: oral administration of Tamsulosin
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT04464070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PGD2
Description: labeled precursor
Study NCT03669224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano Care Gold
Description: Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position
Study NCT03944889 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goniometer
Description: A device to measure angular position
Study NCT00869609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLB Traditional Maintenance (TM)
Description: After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
Study NCT00869609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLB-Carb-focused Maintenance (CF)
Description: After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-MP (6-Mercaptopurine)
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01920737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01920737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study NCT01920737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT/PET scans
Description: PET or CT scan every 6 months for 3 years
Study NCT01424566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Study NCT01424566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (GA-0034)
Study NCT02759536 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boronophenylalanine and IHNI-based BNCT
Description: Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
Study NCT03029507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Enhanced ShipShape
Description: The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
Study NCT03029507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ShipShape (SS)
Description: The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
Study NCT01295424 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no interventions
Study NCT02340390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G7
Description: The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
Study NCT02340390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exceed ABT
Description: The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
Study NCT04326855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walking protocol (ISWT)
Description: Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
Study NCT04326855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance shuttle walking (ESW) protocol
Description: Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
Study NCT04326855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Intermittent shuttle walking protocol
Description: All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
Study NCT04326855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second Intermittent shuttle walking protocol
Description: To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
Study NCT04326855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group study
Description: Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263726
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study NCT01981681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study NCT00689793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
Study NCT00689793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes.
Study NCT03102567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 50mg q.d.
Description: oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
Study NCT03102567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
Study NCT03102567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 250 loading dose and 50mg q.d. maintenance dose
Description: Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
Study NCT03522727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single self-incentivising implementation intention
Description: Participants are asked to form a single self-incentivising implementation intention (if-then plans)
Study NCT02515955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine Matching Placebo
Description: Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study NCT03522727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple self-incentivising implementation intentions
Description: Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
Study NCT03522727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-generated self-incentivising implementation intentions
Description: Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
Study NCT02189707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium 1x1010 cfu
Description: Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
Study NCT02189707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium 1x109 cfu
Description: Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
Study NCT02189707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder in capsules
Description: Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
Study NCT02591459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Using the app to assist routine anticipation
Description: Using the app to assist routine anticipation for autistic children in Android mobile devices
Study NCT03917550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery (Transdiagnostic & self)
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
Study NCT03917550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
Study NCT02179541 — intervention group
Intervention type: OTHER
Intervention: RGB
Description: When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
Study NCT03598751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Description: 120 mg / 2 mL subcutaneously
Study NCT03598751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL
Study NCT00888641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Surround kidney in ice slush for 10 minutes after arterial clamping
Study NCT03028987 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
Study NCT03028987 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
Study NCT00940784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Description: Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
Study NCT00940784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, aspirin (81-100 mg qd) plus hydroxyurea